Author:
Salem Heba F.,El-Menshawe Shahira F.,Khallaf Rasha A.,Rabea Yasmine K.
Publisher
Springer Science and Business Media LLC
Reference63 articles.
1. Campbell N, Young ER, Drouin D, Legowski B, Adams MA, Farrell J, et al. A framework for discussion on how to improve prevention, management, and control of hypertension in Canada. Can J Cardiol. 2012;28(3):262–9.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.
3. Chonkar AD, Rao JV, Managuli RS, Mutalik S, Dengale S, Jain P, et al. Development of fast dissolving oral films containing lercanidipine HCl nanoparticles in semicrystalline polymeric matrix for enhanced dissolution and ex vivo permeation. Eur J Pharm Biopharm. 2016;103:179–91.
4. Subhash P, Dinesh B, Ravikumar M. Assessment of Lercanidipine hydrochloride for transdermal delivery: physiochemical, in-vitro and ex-vivo characterization of matrix type Lercanidipine hydrochloride transdermal patches. Int J Pharm Biol Sci. 2012;3:349–65.
5. Deshpande PB, Gurram AK, Deshpande A, Shavi GV, Musmade P, Arumugam K, et al. A novel nanoproliposomes of lercanidipine: development, in vitro and preclinical studies to support its effectiveness in hypertension therapy. Life Sci. 2016;162:125–37.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献